AMGEN INC cotiza a 412.84 USD y tiene una capitalización bursátil de $223.2B. En los últimos 12 meses ha facturado $38.1B con un margen de flujo de caja libre del 22.0%. Cotiza a 21.9 veces su flujo de caja libre (P/FCF) y a un PER de 25.5. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral u…
| Periodo | 2026-11 | 2026-08 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $6.29 | $5.15 | $5.29 |
| Estimado | $5.76 | $5.62 | $4.77 | $4.73 |
| Sorpresa | — | +11.9% | +8.0% | +11.8% |
| Métrica | AMGN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 67.3% | 57.0% | +10.2% |
| Operating Margin | 24.7% | -38.6% | +63.3% |
| Net Margin | 21.0% | -33.6% | +54.5% |
| FCF Margin | 22.0% | -13.9% | +35.9% |
| ROE | 89.1% | -40.4% | +129.5% |
| ROA | 8.5% | -32.0% | +40.5% |
| Current Ratio | 1.14 | 2.84 | -1.70 |
| Debt / Equity | 6.31 | 0.28 | +6.03 |